EUVIMEDEUVIMED entdecken
Multizentrische Studie

Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors—Data From the ARON-1 Study

Francesco Massari iD, Matteo Rosellini iD, Bohuslav Melichar, Enrique Grande iD, Maria T Bourlon iD, Haoran Li iD, Ondřej Fiala iD, Se Hoon Park iD, Maria José Juan Fita iD, Tarek Taha iD, Javier Molina-Cerrillo iD, Daniele Santini und 21 weitere

JCO Global Oncology · 2025-10 · (11)

DOI: 10.1200/go-25-00376 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JCO Global Oncology, 2025-10. Verfasst von Francesco Massari und 32 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Sarcomatoid renal cell carcinoma (sRCC) represents a kidney malignancy with a sarcomatoid component associated with poor prognosis. Immunotherapy (IO)-based combinations demonstrated promising activity in sRCC, yet real-world evidence (RWE) remains limited. We aimed to characterize the clinicopathologic features and outcomes of patients with metastatic sRCC treated with first-line immune-based combinations. PATIENTS AND METHODS This retrospective analysis from the ARON-1 study included 350 patients with histologically confirmed metastatic sRCC treated with first-line IO + IO, or IO + tyrosine kinase inhibitor across 66 centers in 21 countries (2016-2024). Overall survival (OS) was analyzed using Kaplan-Meier and Cox regression methods. Correlations between 2-year OS and clinical variables were assessed using Pearson's coefficient. RESULTS After a median follow-up of 19.1 months, median OS was 26.9 months (95% CI, 21.6 to 43.3). OS was longer in males (43.3 v 15.3 months in females; P < .001), in whom underwent nephrectomy (32.3 v 20.7 months; P = .002), and in patients without hepatic (32.3 v 15.3 months; P < .001), without skeletal (41.0 v 20.0 months; P = .007), or without lymph node metastases (43.3 v 24.6 months; P = .037). Median OS varied by International Metastatic RCC Database Consortium (IMDC) risk group: 66.5, 29.4, and 11.7 months in favorable-, intermediate-, and poor-risk patients, respectively ( P < .001). Different IO regimens showed variable outcomes by risk subgroup. Limitations include retrospective design and lack of central pathology review. CONCLUSION First-line IO-based combinations provide clinically meaningful survival in sRCC, with outcomes affected by sex, metastatic sites, and IMDC risk. This RWE may support a tailored therapeutic approach on the basis of baseline prognostic factors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsImmune Checkpoint InhibitorsHumansMaleFemaleMiddle AgedRetrospective StudiesAgedAdultTreatment OutcomePrognosis

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
  • Department of Oncology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic.
  • Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain.
  • Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
  • Division of Medical Oncology, Department of Internal Medicine, University of Kansas Cancer Center, Kansas City, MO.

ORCID-Profile: Francesco Massari, Matteo Rosellini, Enrique Grande, Maria T Bourlon, Haoran Li, Ondřej Fiala, Se Hoon Park, Maria José Juan Fita, Tarek Taha, Javier Molina-Cerrillo, Alfonso Gómez de Liañ, Thomas Büttner, Sarah Scagliarini, Ray Manneh Kopp, Annalisa Zeppellini, Marwan Ghosn, Hatice Bölek, Jawaher Ansari, Ahmet Yildirim, Umut Akova, Fernando Sabino Marques Monteiro, Sebastiano Buti, Andrey Soares, Mehmet Asim Bilen, Yüksel Ürün

Zitieren

APA

Massari, F., Rosellini, M., Melichar, B., Grande, E., Bourlon, M. T., Li, H., Fiala, O., Park, S. H., Fita, M. J. J., Taha, T., Molina-Cerrillo, J., Santini, D., de Liañ, A. G., Büttner, T., Scagliarini, S., Manneh Kopp, R., Zeppellini, A., Ghosn, M., Conteduca, V., …, & Santoni, M. (2025). Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors—Data From the ARON-1 Study. JCO Global Oncology. https://doi.org/10.1200/go-25-00376

Vancouver

Massari F, Rosellini M, Melichar B, Grande E, Bourlon MT, Li H, et al. Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors—Data From the ARON-1 Study. JCO Global Oncology. 2025. doi:10.1200/go-25-00376

BibTeX
@article{Massari2025,
  author = {Massari, Francesco and Rosellini, Matteo and Melichar, Bohuslav and Grande, Enrique and Bourlon, Maria T and Li, Haoran and Fiala, Ondřej and Park, Se Hoon and Fita, Maria José Juan and Taha, Tarek and Molina-Cerrillo, Javier and Santini, Daniele and de Liañ, Alfonso Gómez and Büttner, Thomas and Scagliarini, Sarah and Manneh Kopp, Ray and Zeppellini, Annalisa and Ghosn, Marwan and Conteduca, Vincenza and Bölek, Hatice and Rizzo, Alessandro and Ansari, Jawaher and Mollica, Veronica and Zgura, Anca and Filosa, Alessandra and Yildirim, Ahmet and Akova, Umut and Monteiro, Fernando Sabino Marques and Buti, Sebastiano and Soares, Andrey and Bilen, Mehmet Asim and Ürün, Yüksel and Santoni, Matteo},
  title = {Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors—Data From the ARON-1 Study},
  journal = {JCO Global Oncology},
  year = {2025},
  number = {11},
  doi = {10.1200/go-25-00376}
}
Kostenlos starten →